Life Sciences Workshop: Updates and Recent Trends in Pharmaceutical and Biotechnology Patent Law

Patent practice in the life sciences is constantly evolving. New USPTO Guidance on 35 U.S.C. § 101 has been issued. The Federal Circuit has continued to face a plethora of issues that go to the very heart of our patent system, including basic questions, such as when subject matter is patentable, what the presumptions are in deciding validity, and even the appropriate standards of review from the Patent Trial and Appeal Board (PTAB) and district court proceedings. The PTAB, while initially slow to start with respect to pharmaceutical and biotechnology proceedings, has gained momentum. There are now a number of significant decisions in this area, and new rules were recently issued that may significantly change IPR practice. While much of the attention has focused on post-grant challenges, pre-grant challenges offer an important option in evaluating your competitor’s patent portfolio. Please join us as we address these issues and provide insight to help guide your practice, including on:

• USPTO Guidance on 35 U.S.C. § 101: Update
• Federal Circuit Case Law: Update
• Pre-grant Challenges
• Hatch-Waxman and Post-Grant Proceedings: Updates, Interplay, Statistics and New Rules

Due to space limitation, please register early.

Speakers:
Howard W. Levine
Jill K. MacAlpine, Ph.D.
Leslie A. McDonell
Amanda K. Murphy, Ph.D.
Sanya Sukduang

Date: 
Thursday, May 19, 2016

Time:
1:30 - 2:00 p.m. – Registration
2:00 - 5:15 p.m. – Workshop
5:15 - 6:30 p.m. – Reception

Location:
Finnegan
Two Seaport Lane
Boston, MA 02210